The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial decrease in body size and improve metabolic function, partic